
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is a biopharmaceutical company that is focused on discovering, developing and commercializing genetic medicines based on editing RNA. With a unique approach to targeting diseases through RNA editing, Korro Bio has the potential to address a significant unmet need in the treatment of rare and prevalent diseases. Its strong pipeline, including its lead program KRRO-121, has shown promising results in preclinical studies and has a clear regulatory path. With a substantial market opportunity and a differentiated product profile, Korro Bio's stock has significant potential for growth and value creation.
Bears say
Korro Bio is currently generating minimal revenue and has a highly speculative pipeline of RNA-editing therapies, which has not yet been proven through clinical trials. While the ASGCT data shows promising initial results, there is still a long road ahead to translate these findings into successful, marketable treatments. Therefore, the company's financial viability and potential success are uncertain at this time, leading to a negative outlook.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares